Skip to Content
Merck
All Photos(1)

Key Documents

SRP6307

Sigma-Aldrich

BPI from human neutrophils

≥95% (SDS-PAGE)

Synonym(s):

BPI, Bacterial/Permeability, CAP57, Increasing Protein

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
12352200
NACRES:
NA.32

biological source

human (neutrophils)

Assay

≥95% (SDS-PAGE)

form

frozen liquid

mol wt

55 kDa

packaging

pkg of 100 μg
pkg of 50 μg

UniProt accession no.

P17213

shipped in

dry ice

storage temp.

−70°C

Gene Information

human ... BPI(671)

General description

Bactericidal/permeability increasing protein (BPI) is a 456 residue protein which is part of the innate immune system. BPI was initially identified in neutrophils, but is found in other tissues including the epithelial lining of mucus membranes. It is an endogenous antibiotic protein with potent killing activity against Gram-negative bacteria. It binds to compounds called lipopolysaccharides produced by Gram-negative bacteria. Lipolysaccharides are potent activators of the immune system; however BPI at certain concentrations can prevent this activation. Bacterial/Permeability-Increasing Protein (BPI) is present in the azurophilic granules of polymorphonuclear leukocytes (PMN). BPI is toxic only toward Gram-negative bacteria. This specificity is attributable to the strong attraction of BPI for the lipopolysaccharides (LPS) in the bacterial envelope. BPI is also an important antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in vasculitis.

Physical form

Frozen in 80 mM Citrate Phosphate, pH 5.6, 0.75 M NaCl.

Storage Class Code

13 - Non Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Maria K Magnusson et al.
Inflammatory bowel diseases, 23(6), 956-966 (2017-04-27)
The clinical disease course of ulcerative colitis (UC) varies substantially between individuals and can currently not be reliably predicted. The gut microbiota and the host's immune defense are key players for gut homeostasis and may be linked to disease outcome.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service